INT47714

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 1995
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 11.12
Pain Relevance 1.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Nqo1) oxidoreductase activity (Nqo1) cytoplasm (Nqo1)
Anatomy Link Frequency
mature B cells 1
muscle 1
pre-B cells 1
plasmablasts 1
Nqo1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 132 98.68 Very High Very High Very High
anesthesia 1 98.08 Very High Very High Very High
isoflurane 1 97.64 Very High Very High Very High
Multiple sclerosis 124 95.20 Very High Very High Very High
ischemia 5 94.40 High High
Inflammatory mediators 7 93.72 High High
Central nervous system 432 92.96 High High
Spinal cord 209 90.96 High High
Demyelination 18 65.52 Quite High
imagery 15 61.88 Quite High
Disease Link Frequency Relevance Heat
Neuromyelitis Optica 1643 100.00 Very High Very High Very High
Disease 447 100.00 Very High Very High Very High
Multiple Sclerosis 217 100.00 Very High Very High Very High
INFLAMMATION 141 98.68 Very High Very High Very High
Autoimmune Disease 155 96.48 Very High Very High Very High
Infection 133 95.28 Very High Very High Very High
Syndrome 54 94.48 High High
Cv Unclassified Under Development 5 94.40 High High
Targeted Disruption 137 87.84 High High
Blindness 15 84.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
According to these authors, NOS immunoreactivity and NADPH-diaphorase technique showed identical results.
Regulation (immunoreactivity) of NADPH-diaphorase
1) Confidence 0.24 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1373636 Disease Relevance 0 Pain Relevance 0
The activities of superoxide dismutase and DT-diaphorase were unaffected by OA treatment.
Neg (unaffected) Regulation (unaffected) of DT-diaphorase
2) Confidence 0.23 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7473165 Disease Relevance 0 Pain Relevance 0
Increased NADPH diaphorase activity and NOS immunoreactivity were histochemically detected in the cells of muscle that had been subjected to I/R.
Regulation (immunoreactivity) of NADPH diaphorase in muscle
3) Confidence 0.10 Published 2003 Journal Leg Med (Tokyo) Section Abstract Doc Link 12935594 Disease Relevance 0.40 Pain Relevance 0.28
NMO is a devastating disease affecting primarily young women (relapsing NMO) but either sex can develop monophasic NMO, and NMO rarely occurs in adolescents.
Regulation (affecting) of NMO associated with neuromyelitis optica and disease
4) Confidence 0.03 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 2.08 Pain Relevance 0.26
Therapies that are effective in NMO patients are those that, modify inflammation (gene activation events), reduce lymphocyte proliferation, remove serum immunoglobulin and other components and in the case of the anti-CD20 monoclonal antibody, kill pre-B cells, mature B cells, and plasmablasts, but not lymphocyte stems cells or plasma cells.
Regulation (effective) of NMO in mature B cells associated with neuromyelitis optica and inflammation
5) Confidence 0.02 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 1.30 Pain Relevance 0.21
Further, not all cells that express AQP4 exhibit pathologic changes in NMO patients.
Regulation (changes) of NMO associated with neuromyelitis optica
6) Confidence 0.02 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 0.99 Pain Relevance 0.12
The differences in spot volume was used as a measure of changes in protein expression levels between the NMO and control groups, and were ascertained statistically by the Mann–Whitney U-test, where a p value <0.05 was considered significant.
Regulation (changes) of NMO associated with neuromyelitis optica
7) Confidence 0.02 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2730746 Disease Relevance 0.10 Pain Relevance 0
The distribution of NMO immunoreactivity showed the water channel protein, AQP4, as a candidate antigen.
Regulation (immunoreactivity) of NMO associated with neuromyelitis optica
8) Confidence 0.01 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 0.90 Pain Relevance 0
Epigenetic events-major or minor role in NMO
Regulation (role) of NMO associated with neuromyelitis optica
9) Confidence 0.01 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 1.59 Pain Relevance 0.25
Tissues that are the targets of pathology in EAE and NMO can overlap but the details of the immune response and the autoantigen can shape the final effector phases.
Regulation (targets) of NMO associated with neuromyelitis optica and multiple sclerosis
10) Confidence 0.01 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 1.17 Pain Relevance 0.17
Therapies that are effective in NMO patients are those that, modify inflammation (gene activation events), reduce lymphocyte proliferation, remove serum immunoglobulin and other components and in the case of the anti-CD20 monoclonal antibody, kill pre-B cells, mature B cells, and plasmablasts, but not lymphocyte stems cells or plasma cells.
Regulation (effective) of NMO in pre-B cells associated with neuromyelitis optica and inflammation
11) Confidence 0.01 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 1.30 Pain Relevance 0.21
Therapies that are effective in NMO patients are those that, modify inflammation (gene activation events), reduce lymphocyte proliferation, remove serum immunoglobulin and other components and in the case of the anti-CD20 monoclonal antibody, kill pre-B cells, mature B cells, and plasmablasts, but not lymphocyte stems cells or plasma cells.
Regulation (effective) of NMO in plasmablasts associated with neuromyelitis optica and inflammation
12) Confidence 0.01 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2427020 Disease Relevance 1.30 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox